Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FleuryBSP:FLRY3 -1.22%84 3-Year EBITDA Growth Rate is 3.40% as of Mar. 2026, which is 76% below its 10-year median of 14.20. GuruFocus rates BSP:FLRY3 with a GF Score™ of 84/100 and a GF Value™ of R$17.27 (Fairly Valued). The stock has 9 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Fleury ranks worse than 59.39% on this metric.
During the past 12 months, Fleury's average EBITDA Per Share Growth Rate was 10.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fleury was 28.10% per year. The lowest was 3.40% per year. And the median was 14.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Fleury 3-Year EBITDA Growth Rate Related Terms
BSP:FLRY3 vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Fleury's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Fleury's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.40% mean?
Fleury (BSP:FLRY3) has a 3-Year EBITDA Growth Rate of 3.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fleury and its competitors. This is 76% below median its historical median of 14.20. Over the past decade, Fleury's 3-Year EBITDA Growth Rate has ranged from 3.40 to 28.10. According to the industry distribution chart, Fleury ranks #98 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 59.4%.
Is Fleury's 3-Year EBITDA Growth Rate too high?
Fleury's current 3-Year EBITDA Growth Rate of 3.40% is 76% below median its 10-year median of 14.20. Over the past 10 years, this metric has ranged from a low of 3.40 to a high of 28.10. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.50. Fleury's value of 3.40% is 70.4% below this industry median. Based on the distribution chart, Fleury ranks #98 out of 165 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Fleury has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fleury's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #98 out of 165 companies for 3-Year EBITDA Growth Rate. This places Fleury in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.50. Fleury's value of 3.40% is 70.4% below this benchmark. Historically, Fleury's own 3-Year EBITDA Growth Rate has ranged from 3.40 to 28.10 over the past decade. While the company's 10-year median is 14.20 vs. the industry median of 11.50, Fleury has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.50, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current 3-Year EBITDA Growth Rate of 3.40% is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fleury and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current 3-Year EBITDA Growth Rate is 3.40%, which is 76% below median its own 10-year median of 14.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Fairly Valued. The stock's GF Value™ is R$17.27, compared to a current price of R$18.59 — trading 7.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.40%, which is 76% below median its 10-year median of 14.20 and 70.4% below the Medical Diagnostics & Research industry median of 11.50. Fleury's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current 3-Year EBITDA Growth Rate is 3.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be overvalued.
The current stock price of R$18.59 is trading 7.6% above its estimated GF Value™ of R$17.27.
GuruFocus considers Fleury to be Fairly Valued.
Key valuation signals for BSP:FLRY3:
3-Year EBITDA Growth Rate: 3.40% (76% below median its 10-year median of 14.20)
GF Value™: R$17.27 vs. price of R$18.59 (7.6% above fair value)
Industry Position: 70.4% below the Medical Diagnostics & Research median (#98 of 165)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
84GF Score
Get the complete analysis for BSP:FLRY3
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
